Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report.

Authors

Yamato Numata, Go Kimura, Jun Akatsuka, Hikaru Mikami, Kotaro Obayashi, Yuki Endo, Hayato Takeda, Yuka Toyama, Ryuji Ohashi, Yukihiro Kondo

Published in

IJU case reports. Volume 9. Issue 4. Pages e70224. Epub Jul 13, 2026.

Abstract

The combination of enzalutamide and radium-223 has demonstrated clinical efficacy in metastatic castration-resistant prostate cancer; however, real-world evidence remains limited, particularly with PSA-discordant progression.
A 74-year-old man with high-risk localized prostate cancer was treated with androgen deprivation therapy followed by definitive external beam radiotherapy. Eight months later, the disease progressed radiographically with extensive bone, nodal, and solitary liver metastases, while prostate-specific antigen levels remained persistently low, consistent with prostate-specific antigen-discordant progression. Bone turnover markers and disease activity markers were markedly elevated. Combination therapy with enzalutamide and radium-223 was initiated, and six cycles of radium-223 were completed. Following treatment, skeletal disease activity and bone turnover markers improved markedly. Apart from grade 3 anemia requiring transfusion, no severe adverse events occurred.
This case suggests that enzalutamide combined with radium-223 may provide clinical benefit in metastatic castration-resistant prostate cancer with PSA-discordant progression.

PMID:
42453858
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.